tella, Inc.Company Review & Valuation

2191
Tokyo Stock Exchange

About tella, Inc.

tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It also offers technology and know-how to medical institutions such as university hospitals and national hospitals. It operates through the following business segments: Cell Medicine, Medical Support, and PharmacShow more euticals. The Cell Medicine segment involves the provision of cancer treatment technologies and know-how, chiefly the dendritic cell (DC) vaccine therapy. The Medical Support segment deals with the operation of cell processing facilities by contract, the provision of maintenance and management services for these facilities, sales of cell processing devices, sales of small-amount short-term insurance, and the genetic diagnosis support business, and others. The Pharmaceuticals segment handles development activities for the purpose of receiving pharmaceutical approval of the DC vaccine as a regenerative medicine product for treating cancer. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. Show less

Industry
Other
HQ Location
Tokyo, Japan

Stock Price

Price data not available for tella, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

back to top